A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Resected Solid Tumors And Unresectable Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    Patients with any of the following solid malignancies: a. Non-small cell lung cancer lacking EGFR sensitizing mutant on or ALK translocation per local test results b. Small cell lung cancer c. Melanoma d. Bladder urothelial carcinoma e. Human papillomavirus-negative HNSCC f. Any solid malignancy known to be MSI high MMR efficient (including but not limited to; CRC, stomach adenocarcinoma, esophageal adenocarcinoma and endometrial cancer) 2. Patients must have resolution of toxic effect(s) from prior therapy 3. Patients must have one of the histologically-confirmed solid malignancies OR Patients must have one of the histologically- or cytological -confirmed unresectable (locally advanced or metastatic) solid malignancies

You may not be eligible for this study if the following are true:

  • 1. Active central nervous system metastases and/or carcinomatous meningitis. 2. Active autoimmune disease that has required systemic treatment in past 2 years 3. Has a history of (noninfectious) pneumonitis that required steroids or current pneumonitis.
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.